Home » Stocks » HSKA

Heska Corporation (HSKA)

Stock Price: $127.49 USD 1.14 (0.90%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.21B
Revenue (ttm) 166.77M
Net Income (ttm) -18.59M
Shares Out 9.45M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE 243.90
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $127.49
Previous Close $126.35
Change ($) 1.14
Change (%) 0.90%
Day's Open 125.80
Day's Range 125.62 - 128.39
Day's Volume 37,401
52-Week Range 50.00 - 140.00

More Stats

Market Cap 1.21B
Enterprise Value 1.17B
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 9.45M
Float n/a
EPS (basic) -2.23
EPS (diluted) -2.27
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 216,609
Short Ratio 3.35
Short % of Float n/a
Beta 1.71
PE Ratio n/a
Forward PE 243.90
P/FCF Ratio n/a
PS Ratio 7.23
PB Ratio 4.39
Revenue 166.77M
Operating Income -8.09M
Net Income -18.59M
Free Cash Flow -2.34M
Net Cash 31.23M
Net Cash / Share 3.30
Gross Margin 32.65%
Operating Margin -4.85%
Profit Margin -11.10%
FCF Margin -1.40%
ROA -0.13%
ROE -8.90%
ROIC -5.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 2
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$141.00*
(10.60% upside)
Low
95.0
Current: $127.49
High
167.0
Target: 141.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12312712913010589.8478.3472.8170.0765.45
Revenue Growth-3.75%-1.47%-0.57%24.37%16.43%14.68%7.6%3.91%7.05%-
Gross Profit54.4556.6458.2653.8944.2135.7230.6331.1029.1924.79
Operating Income0.333.7918.2216.538.562.91-1.432.163.250.36
Net Income-1.475.859.9510.515.242.60-1.201.202.150.02
Shares Outstanding7.457.227.036.786.515.955.765.335.245.22
Earnings Per Share-0.200.741.301.430.740.41-0.210.220.40-
EPS Growth--43.08%-9.09%93.24%80.49%---45%--
Operating Cash Flow3.3013.2910.415.862.135.55-1.41-0.374.891.94
Capital Expenditures-1.04-4.08-3.41-3.42-3.77-2.333.09-1.51-1.08-0.62
Free Cash Flow2.259.207.002.44-1.653.221.68-1.883.801.32
Cash & Equivalents92.8916.389.6610.796.895.866.025.786.335.49
Total Debt52.636.006.000.750.370.425.302.55-3.08
Net Cash / Debt40.2610.383.6610.046.525.440.723.236.332.41
Assets24415613513111096.8493.5566.8361.8963.05
Liabilities89.8934.0435.0043.8730.4428.0329.3717.9613.4617.25
Book Value15412210086.9847.7837.4533.4648.8648.4445.80
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Heska Corporation
Country United States
Employees 386
CEO Kevin S. Wilson

Stock Information

Ticker Symbol HSKA
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: HSKA
IPO Date June 30, 1997

Description

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud and HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.